Upgrade to SI Premium - Free Trial

Piper Sandler Reiterates Overweight Rating on Moderna (MRNA) Following FDA Approval of mRNA Flu Vaccine

August 6, 2026 8:42 AM
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and a $77.00 price target on Moderna (NASDAQ: MRNA) following the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles